Figure 7. High IL1RAP expression is associated with longer survival in nadunolimab-treated patients. (A) Representative histology slides where cancer cells (upper panels) and stroma cells (lower panels). Tumor and stroma cells were scored as having low IL1RAP expression (Tumor cell H-score ≤100, and stroma staining intensity assessment ≤1, left panels) or high IL1RAP expression (Tumor cell H-score >100 and stroma staining intensity assessment >1, right panels). (B) Progression-free and overall survival of PDAC patients receiving nadunolimab as monotherapy, with survival analysis based on low or high combined IL1RAP expression in the tumor. The combined score was defined as high when both the tumor cells and stromal cells scored high according to the above criteria (N=5). All other samples were categorized as having a low combined score (N=10). Significance in the survival analysis was tested by log-rank (Mantel-Cox) test.